NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization724.82 mln
Float271 mln
Earnings Date08/05/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
8.48
Transformational upside
Relative Strength
20
/ 100
Significantly lagging
Debt / Equity
0.26
Very low leverage
ROE
-53.74
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing cancer and autoimmune disease treatments using off-the-shelf T cell therapies derived from donor cells rather than a patient's own. Founded in 2017 and based in South San Francisco, the company is advancing several treatment candidates, including therapies targeting blood cancers, kidney cancer, and conditions such as lupus. Its lead programs include cema-cel for large B-cell lymphoma and ALLO-329, which addresses multiple autoimmune diseases by targeting two proteins simultaneously.
